

Suriname

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.014 (0.014–0.015)	2.6 (2.5–2.8)
Mortality (HIV+TB only)	0.011 (<0.01–0.024)	2 (0.54–4.4)
Incidence (includes HIV+TB)	0.18 (0.14–0.23)	33 (26–42)
Incidence (HIV+TB only)	0.055 (0.042–0.07)	10 (7.8–13)
Incidence (MDR/RR-TB)**	0.024 (0.011–0.037)	4.4 (2–6.8)

Estimated TB incidence by age and sex (thousands)*, 2015

	0-14 years	> 14 years	Total
Females	0.01 (<0.01–0.014)	0.053 (0.027–0.079)	0.063 (0.032–0.093)
Males	<0.01 (<0.01–0.011)	0.11 (0.082–0.14)	0.12 (0.087–0.15)
Total	0.018 (0.012–0.024)	0.16 (0.14–0.19)	0.18 (0.14–0.23)

TB case notifications, 2015

Total cases notified	150
Total new and relapse	144
- % tested with rapid diagnostics at time of diagnosis	78%
- % with known HIV status	97%
- % pulmonary	83%
- % bacteriologically confirmed among pulmonary	77%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	80% (64–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.14 (0.08–0.22)

TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	42	30%
- on antiretroviral therapy	26	62%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			14 (5–23)
Estimated % of TB cases with MDR/RR-TB	9.9% (4.1–19)	25% (0.63–81)	
% notified tested for rifampicin resistance	77%	40%	112
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 8, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	77%	146
Previously treated cases, excluding relapse, registered in 2014	33%	12
HIV-positive TB cases, all types, registered in 2014	68%	37
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016

National TB budget (US\$ millions)	1.6
Funding source: 57% domestic, 35% international, 8% unfunded	

* Ranges represent uncertainty intervals


** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence
— Notified (new and relapse)
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

